Daclatasvir联合asunaprevir治疗基因1b型慢性丙型肝炎1例报告

Daclatasvir和asunaprevir作为直接抗病毒药物来联合治疗基因1b型慢性丙型肝炎患者，可获得较高的持续病毒学应答率。目前国内尚无使用该方案治疗基因1b型患者的报道。本文报告1例基因1b型慢性丙型肝炎青年女性患者使用该方案治疗24周，获得持续病毒学应答，最后临床治愈；但出现一过性胆红素升高、轻度血红蛋白下降，波动于100~110 g/L。

Combined therapy with daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b:a case report

The combination therapy with daclatasvir and asunaprevir can achieve a high sustained viral response rate against hepatitis C virus (HCV) genotype 1, but so far this regimen has not been reported in the treatment of Chinese patients with chronic hepatitis C (CHC) genotype 1b. Here we report a case of CHC genotype 1b in a 44-year-old female chinese patient who was treated with this regimen for 24 weeks. The patient showed sustained viral response after the treatment and was clinically cured. During the treatment, the patient experienced a transient elevation of serum total bilirubin accompanied by lowered hemoglobin fluctuating between 100 and 110 g/L.